Exelixis Inc.

Organization Address
249 East Grand Avenue, PO Box 511
South San Francisco, CA 94083-0511

Organization Phone
(650) 837-7000



Organization Description

Clinical Trials Exelixis is currently conducting a comprehensive clinical development program for cabozantinib in prostate cancer. Several Exelixis-sponsored trials in other cancer indications have completed enrollment and continue to generate data that will inform future development in other types of cancer. Additional clinical trials are being conducted under a Cooperative Research and Development Agreement with the National Institute’s of Health Cancer Therapy Evaluation Program and through our Investigator Sponsored Trial program. Collaborations Our early-stage discovery and research expertise has generated multiple compounds and programs that target key pathways in cancer and metabolic diseases. We have established collaborations with leading pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. (a wholly-owned member of the Roche Group), GlaxoSmithKline, Sanofi, Merck (known as MSD outside of the United States and Canada) and Daiichi-Sankyo Company Limited, for a variety of our compounds and programs. Pursuant to these collaborations, we have out-licensed compounds or programs to a partner for further development and commercialization, generally have no further unfunded cost obligations related to such compounds or programs and may be entitled to receive research funding, milestones and royalties or a share of profits from commercialization. Working with these leaders in the fields of cancer and metabolic disease ensures that our innovative compounds are being developed effectively.

Clinical Development Stage
Approved; IND; NDA; Phase I; Phase II; Phase III; PreClinical